The DAWN antivirals trial: process evaluation of a COVID-19 trial in general practice
Description
CONCLUSION: The DAWN Antivirals trial was stopped prematurely. Although many barriers were related to the pandemic itself, hurdles such as small and inexperienced sponsor and clinical teams, delays in regulatory processes and research capacity in
